Introduction: In the last years it has been proved that matrix metalloproteinases participate in the development of all stages of atherosclerotic process. It has been suggested that plasma levels of metalloproteinases can be a novel, inflammatory marker of atherosclerosis. THE AIM OF THE STUDY was to evaluate plasma levels of selected matrix metalloproteinases (MMP-2 and MMP-9) in obese children and adolescents.
Material And Methods: We studied 45 children and adolescents with simple obesity aged 15+/-1.8 years. The control group comprised 28 healthy, slim children aged 14.5 years. The obese children were studied according to coexistence of hypertension, hyperlipidemia, positive family history of cardiovascular diseases and insulin resistance. Levels of matrix metalloproteinases were assessed by use of ready ELISA kits (R&D Systems).
Results: MMP-9 level in the study group equaled 553.5+/-311 ng/ml and was significantly higher compared to the control group: 400.4+/-204 ng/ml, p=0.02. MMP-2 level in the study group was significantly lower compared to the control group: 211+/-37 ng/ml vs. 258+/-56 ng/ml, p<0,0001. In obese children with coexisting hypertension we found higher levels of MMP-9 when compared to children with obesity only: 635+/-308 ng/ml vs. 450+/-289 ng/ml (p=0,04), MMP-2 levels remained similar in both groups.
Conclusions: Different levels of plasma matrix metalloproteinases in obese and hypertensive children compared to healthy, slim controls can indicate an altered metabolism of the extracellular matrix (ECM) of vessels and heart muscle. Changed metabolism of ECM may be of significant importance in enhancing the atherosclerotic process in this young patients.
Download full-text PDF |
Source |
---|
Background: Overexpression of tear matrix metalloproteinases-9 (MMP-9) on the ocular surface tissues has been reported to result in ocular surface damage. MMP-9 levels in tears have been listed as one of many tools for confirming dry eye disease (DED).
Objective: This investigation aimed to compare MMP-9 levels and ocular surface parameters in diabetic patients with and without DED.
Tissue Cell
December 2024
Department of Orthopaedics, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China. Electronic address:
Age-related diseases are often linked to chronic inflammation. Senescent cells secrete inflammatory cytokines, chemokines and matrix metalloproteinases, collectively referred to as the senescence-associated secretory phenotype (SASP). The current study discovered that aging leads to the accumulation of senescent tendon stem/progenitor cells (TSPCs) in tendon tissue, resulting in the development of a SASP.
View Article and Find Full Text PDFNat Nanotechnol
January 2025
Wallace H. Coulter Department of Biomedical Engineering, Georgia Tech College of Engineering and Emory School of Medicine, Atlanta, GA, USA.
The forward design of biosensors that implement Boolean logic to improve detection precision primarily relies on programming genetic components to control transcriptional responses. However, cell- and gene-free nanomaterials programmed with logical functions may present lower barriers for clinical translation. Here we report the design of activity-based nanosensors that implement AND-gate logic without genetic parts via bi-labile cyclic peptides.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by hallmark pathologies that affect many brain regions, including the cellular microenvironment with the hippocampus, ultimately leading to profound deficits in cognition. Surprising recent work has shown that factors in the systemic environment regulate the hippocampal cellular niche; age-associated blood-borne factors exacerbate brain aging phenotypes, whereas youth-associated blood-borne factors, including tissue inhibitor of metalloproteinases 2 (TIMP2), reverse or ameliorate features of brain aging. As aging serves as the major risk factor for AD, and recent work shows that systemic factors can regulate AD pathology, we sought to characterize mechanisms by which the systemic environment regulates CNS phenotypes relevant to AD pathology through changes in neuroinflammation.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Indiana University School of Medicine, Stark Neurosciences Research Institute, Department of Neurology, Indianapolis, IN, USA.
Anti-amyloid immunotherapy holds great promise for our patients and their families as the first disease-modifying therapy for the treatment of Alzheimer's disease (AD) to be approved. Positive clinical trials for lecanamab and donanemab showed significant and rapid lowering of brain amyloid burden and a significant slowing of cognitive decline. Amyloid-related imaging abnormalities (ARIA) in the form of vasogenic edema (ARIA-E) and micro - and macro- hemorrhages (ARIA-H) remain the major obstacle to broad use of these agents.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!